Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Horizon Pharma AG

Division of Horizon Therapeutics PLC
www.nitec-pharma.com

Latest From Horizon Pharma AG

Big Pharma Defuses Drug Pricing Landmines On Capitol Hill

Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.

Pricing Debate Legislation

Big Pharma Defuses Drug Pricing Landmines On Capitol Hill

Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.

Pricing Debate Legislation

Cash-guzzling Horizon prices new offering

Horizon Pharma has priced a public offering of common stock and warrants and expects to raise $70 million in net proceeds, or $81 million if an over-allotment option is fully exercised. The offering, which is expected to close on 25 September, will involve the sale of units consisting of one share and a warrant to purchase 0.5 shares priced at $3.50. The company's share price has tumbled by 24% from $4.58 on 19 September before it disclosed its planned offering to $3.49 in mid-morning trading on 21 September following the pricing. The company's market cap was $118 million on 21 September 2012.

Orthopedics Neurology

Horizon to raise $50.8m to fund Duexis launch and Lodotra ambitions

Horizon Pharma plans to raise $50.8 million in a private placement of 14 million units at $3.62 each. One unit will be made up of one share of Horizon common stock and a warrant to purchase 0.25 shares at an exercise price of $4.31 per share. The financing, which is expected to close this week, will raise around $50.8 million.

Orthopedics Respiratory
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Nitec Pharma AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Horizon Therapeutics PLC
  • Senior Management
  • Anders Harfstrand, MD, PhD, CEO
    Harry Welten, CFO
    Jochen Mattis, EVP, Sales & Mktg., Bus. Dev.
    Achim Schaffler, PhD, EVP, R&D/Technical Ops.
  • Contact Info
  • Horizon Pharma AG
    Phone: (41) 61 715 20 40
    Kägenstrasse 17
    Reinach, 4153
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register